Methylcobalamin is one of the naturally active forms of vitamin B12, an essential nutrient the body needs for red blood cell formation, nerve function, and DNA synthesis. It is not a peptide. B12 deficiency treatment is one of the most well-established, FDA-recognized uses in all of nutritional medicine; it is a genuinely different evidence category from most entries in this bioregulator/blend series, and readers should not expect the same level of uncertainty here.
Research snapshot
| Peptide category | Small-molecule vitamin (not a peptide); one of the naturally active coenzyme forms of vitamin B12 |
| Primary research interest | Treatment of B12 deficiency; nerve function, red blood cell formation, DNA synthesis |
| Highest available evidence | Tier 1 — B12 deficiency treatment is one of the most well-established, FDA-recognized uses in nutritional medicine |
| Human research available | Yes, extensive and well established |
| Development status | Established essential nutrient; long-marketed prescription and OTC products |
| Regulatory status | FDA-recognized as an essential nutrient; injectable and oral B12/methylcobalamin products are FDA-approved prescription and OTC products depending on formulation and dose — a fundamentally different regulatory position from the unapproved peptides/blends elsewhere on this site |
| Last reviewed | September 2026 |
Technical identity
| Primary name | Methylcobalamin |
| Alternative names | Vitamin B12 (methylcobalamin is one active coenzyme form; distinct from cyanocobalamin and adenosylcobalamin) |
| Peptide sequence | Not applicable — this is a small-molecule vitamin (corrinoid/cobalamin compound), not a peptide |
| Amino-acid length | Not applicable — this is a small-molecule vitamin, not a peptide |
| Molecular formula | Commonly cited as C63H91CoN13O14P; not independently re-verified in this pass |
| Molecular weight | Commonly cited around 1344.4 g/mol; not independently re-verified in this pass |
| CAS Registry Number | Commonly cited as 13422-55-4; not independently re-verified in this pass |
| PubChem CID | Not independently re-verified in this pass |
| Peptide class | Not applicable — cobalamin (vitamin B12) coenzyme form |
| Primary biological target | Cofactor for methionine synthase and other B12-dependent enzymes involved in red blood cell formation, nerve function, and DNA synthesis |
| Developer or originator | Naturally occurring essential vitamin; not a synthetic invention |
| Development status | Established, long-marketed prescription and over-the-counter product |
What it is
Vitamin B12 (cobalamin) is a water-soluble vitamin the human body cannot make on its own; it must come from diet (primarily animal products) or supplementation. Methylcobalamin is one of the two coenzyme-active forms of B12 that the body actually uses directly (the other being adenosylcobalamin), distinguishing it from cyanocobalamin, a synthetic form that must first be converted in the body before it becomes active. B12 deficiency is a recognized medical condition that can cause anemia (specifically megaloblastic anemia) and neurological problems including numbness, tingling, balance difficulty, and cognitive changes if left untreated.
B12 deficiency treatment and prevention is not a fringe or speculative use — it is standard, guideline-recommended medical care, especially for people with pernicious anemia (an autoimmune condition impairing B12 absorption), strict vegans and vegetarians, older adults with reduced stomach acid, people who have had certain gastrointestinal surgeries (such as gastric bypass), and people taking medications that interfere with B12 absorption (such as long-term metformin or proton pump inhibitors).
Separately from this well-established deficiency-treatment role, methylcobalamin (often as high-dose “B12 shots”) is also marketed for general energy, fatigue, and metabolic-boost purposes in people without diagnosed deficiency. This specific “energy boost in a non-deficient person” framing has much weaker evidence behind it than deficiency treatment itself, and the two uses should not be conflated.
How does it work?
Plain-English explanation
B12 acts as a helper molecule (a coenzyme) for two important chemical reactions in the body: making new DNA (needed to produce healthy red blood cells) and maintaining the protective coating around nerves. When B12 is deficient, red blood cells become abnormally large and immature, and nerve signals can become impaired, which is why deficiency causes both anemia and neurological symptoms.
Technical explanation
Methylcobalamin serves as the cofactor for methionine synthase, an enzyme that converts homocysteine to methionine in the methylation cycle, and is required for normal folate metabolism and DNA synthesis. The related form adenosylcobalamin is the cofactor for methylmalonyl-CoA mutase in fatty acid metabolism; a deficiency of either active form can raise homocysteine and methylmalonic acid (MMA), which are used clinically as biomarkers of B12 status alongside serum B12 itself. Oral absorption of B12 depends on intrinsic factor produced by stomach parietal cells and an intact terminal ileum, which is why conditions affecting either (pernicious anemia, ileal disease, bariatric surgery) impair absorption regardless of dietary intake.
Potential benefits and research applications
Treatment of B12 deficiency and megaloblastic anemia
What is being investigated: correction of B12 deficiency and its hematologic and neurologic consequences. How the effect might occur: direct replacement of a required coenzyme, restoring normal DNA synthesis and nerve myelin maintenance. Evidence: extensive published human clinical evidence spanning decades, and this is a recognized, guideline-supported medical treatment. Strength: strong (Tier 1). Limitation: neurological symptoms present for a long time before treatment may not fully reverse.
Prevention of deficiency in at-risk groups
What is being investigated: whether supplementation prevents deficiency developing in vegans/vegetarians, older adults, and people on interacting medications. How the effect might occur: replacing inadequate dietary or absorbed B12 before deficiency symptoms develop. Evidence: strong observational and clinical evidence supports supplementation in these groups. Strength: strong (Tier 1/2) for prevention in defined at-risk populations. Limitation: routine supplementation is not necessary for people with normal dietary intake, normal absorption, and no risk factors.
Energy, fatigue, and “B12 shots” in non-deficient people
What is being investigated: whether high-dose B12 injections improve energy or fatigue in people who are not B12 deficient. How the effect might occur: unclear; no established mechanism supports an energy benefit beyond correcting an actual deficiency. Evidence: has not been established in people with normal B12 status; clinical trials generally show no meaningful benefit over placebo when baseline B12 is normal. Strength: weak/anecdotal (Tier 5/6) for this specific framing, despite B12 itself being extremely well studied. Limitation: perceived energy benefits in non-deficient users are difficult to distinguish from placebo effect.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research, clinical guidelines, or circulating online. Their inclusion documents what is reported and does not establish what any individual reader should personally take.
Amounts studied in human research / used clinically
For confirmed deficiency, clinical guidelines commonly describe intramuscular cyanocobalamin or hydroxocobalamin regimens such as 1,000 mcg injected daily or every other day for one to two weeks, followed by 1,000 mcg weekly until normalization, then monthly maintenance injections, particularly for pernicious anemia and other absorption disorders where lifelong maintenance is typically needed. Oral high-dose regimens (commonly 1,000-2,000 mcg daily) are also used and are supported by clinical trial evidence showing they can be effective even in some absorption-impaired patients, because a small fraction of oral B12 is absorbed independent of intrinsic factor. Exact regimens vary by cause of deficiency and are determined by a treating clinician based on lab values — this page documents commonly used ranges, not a personal recommendation.
Amounts studied in animal research
Not the primary focus of this entry, given the extensive human clinical and deficiency-treatment literature that governs real-world use; animal pharmacology work exists but is not the operative evidence base for human dosing decisions.
Practitioner and community-reported protocols (non-deficiency “energy shot” use)
Community and med-spa/wellness-clinic marketing for general “energy boost” B12 shots commonly describes 1,000 mcg injections weekly to monthly in people without documented deficiency. This is practitioner/vendor-reported (Tier 5/6) for this specific non-deficiency energy-boosting use, separate from the well-established deficiency-treatment dosing above, and lacks strong controlled-trial support for that particular framing.
What circulates E5
For confirmed B12 deficiency, clinically established regimens (loading injections followed by monthly maintenance, or high-dose oral therapy) are well documented in clinical guidelines and are genuinely evidence-based.
Separately, wellness clinics and med spas commonly market "B12 shots" of about 1,000 mcg weekly to monthly for general energy in people without documented deficiency; this specific use is practitioner/vendor-reported and has much weaker controlled-trial support than deficiency treatment itself.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
B12 is generally considered very safe with a wide margin of safety, including at high doses, because excess is excreted renally and there is no established tolerable upper intake level. Injection-site reactions can occur with shots. Rare reports include allergic reactions (more historically associated with certain injectable formulations) and, uncommonly, worsening of acne in some individuals with high-dose B12 use. Unmasking or masking of other conditions can occur — for example, folate supplementation can mask the anemia of B12 deficiency while neurological damage continues, so accurate diagnosis before treatment matters. As with any injectable product from an unregulated or poorly regulated compounding source, product purity, sterility, and accurate labeling are relevant safety considerations regardless of the underlying vitamin’s excellent safety profile.
Regulatory and developmental status
Vitamin B12, including methylcobalamin, is FDA-recognized as an essential nutrient, and B12 injectable and oral products for deficiency treatment are FDA-approved prescription and over-the-counter products in the United States, depending on formulation and dose. This is a fundamentally different regulatory position from the unapproved peptides and blends elsewhere in this series. Status verified as of the review date below.
Frequently asked questions
What is methylcobalamin?
Methylcobalamin is one of the naturally active, coenzyme forms of vitamin B12, an essential nutrient needed for red blood cell formation and nerve function.
How does methylcobalamin differ from cyanocobalamin?
Methylcobalamin is directly usable by the body as a coenzyme, while cyanocobalamin is a synthetic form that the body must first convert into an active form before use. Both are used clinically; evidence does not clearly show one is superior to the other for correcting deficiency in most people.
What dosage has been studied for B12 deficiency?
Clinical regimens commonly include intramuscular injections such as 1,000 mcg on a loading schedule followed by monthly maintenance, or high-dose oral regimens of roughly 1,000-2,000 mcg daily; the exact plan depends on the cause of deficiency and should be set by a treating clinician based on lab testing.
Does B12 boost energy in people who are not deficient?
This specific claim has much weaker evidence than deficiency treatment itself; controlled research generally does not show a meaningful energy benefit in people with normal B12 levels.
Is methylcobalamin approved by the FDA?
Yes, in the sense that vitamin B12 is a recognized essential nutrient and B12-containing products for deficiency treatment are FDA-approved or regulated as dietary supplements depending on formulation, unlike most other entries in this series.
Who is most at risk of B12 deficiency?
People with pernicious anemia, strict vegans/vegetarians, older adults, people who have had certain gastrointestinal surgeries, and people on medications such as long-term metformin or proton pump inhibitors are at increased risk.
Bottom line
Methylcobalamin (vitamin B12) is a genuinely well-studied, FDA-recognized essential nutrient with strong, guideline-supported clinical evidence for treating and preventing deficiency — a very different evidence position from most peptide entries on this site. The weaker, more speculative use is high-dose “energy shot” marketing to people without documented deficiency, where controlled evidence for a meaningful benefit is limited. The distinction between these two uses matters and should not be blurred.